Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. With experienced management and multiple upcoming ...

Pfizer Inc.'s (PFE) decision to halt the development of its oral GLP-1 candidate due to a potential liver toxicity issue could pose tailwinds for smaller biotech rivals, according to Wall Street ...

JPMorgan says Pfizer’s (PFE) decision to discontinue development of danuglipron, an oral small molecule GLP-1, due to a liver toxicity issue in ...

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for ...